How to buy Orchard Therapeutics stock | $5.23

Orchard Therapeutics plc is a biotechnology business based in the US. Orchard Therapeutics shares (ORTX) are listed on the NASDAQ and all prices are listed in US Dollars. Orchard Therapeutics employs 224 staff and has a trailing 12-month revenue of around 0.00.

Orchard Therapeutics stock price (NASDAQ: ORTX)

Use our graph to track the performance of ORTX stocks over time.

Orchard Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-31.

Latest market close	$5.23
52-week range	$2.80 - $9.08
50-day moving average	$4.02
200-day moving average	$5.92
Wall St. target price	$13.10
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.27

Buy Orchard Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Orchard Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Orchard Therapeutics plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Orchard Therapeutics price performance over time

Historical closes compared with the close of $5.23 from 2021-05-28

1 week (2021-07-21)	N/A
1 month (2021-07-01)	21.91%
3 months (2021-04-30)	-12.25%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

Orchard Therapeutics financials

Revenue TTM	$2.6 million
Gross profit TTM	$1.7 million
Return on assets TTM	-23.14%
Return on equity TTM	-48.77%
Profit margin	0%
Book value	$2.39
Market capitalisation	$355.2 million

TTM: trailing 12 months

Shorting Orchard Therapeutics shares

There are currently 3.6 million Orchard Therapeutics shares held short by investors – that's known as Orchard Therapeutics's "short interest". This figure is 29.3% down from 5.1 million last month.

There are a few different ways that this level of interest in shorting Orchard Therapeutics shares can be evaluated.

Orchard Therapeutics's "short interest ratio" (SIR)

Orchard Therapeutics's "short interest ratio" (SIR) is the quantity of Orchard Therapeutics shares currently shorted divided by the average quantity of Orchard Therapeutics shares traded daily (recently around 612376.76767677). Orchard Therapeutics's SIR currently stands at 5.94. In other words for every 100,000 Orchard Therapeutics shares traded daily on the market, roughly 5940 shares are currently held short.

However Orchard Therapeutics's short interest can also be evaluated against the total number of Orchard Therapeutics shares, or, against the total number of tradable Orchard Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orchard Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Orchard Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0475% of the tradable shares (for every 100,000 tradable Orchard Therapeutics shares, roughly 48 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Orchard Therapeutics.

Find out more about how you can short Orchard Therapeutics stock.

Orchard Therapeutics share dividends

We're not expecting Orchard Therapeutics to pay a dividend over the next 12 months.

Orchard Therapeutics share price volatility

Over the last 12 months, Orchard Therapeutics's shares have ranged in value from as little as $2.8 up to $9.08. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orchard Therapeutics's is 1.1421. This would suggest that Orchard Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Orchard Therapeutics overview

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Frequently asked questions

What percentage of Orchard Therapeutics is owned by insiders or institutions?
Currently 0.123% of Orchard Therapeutics shares are held by insiders and 69.603% by institutions. How many people work for Orchard Therapeutics?
Latest data suggests 224 work at Orchard Therapeutics. When does the fiscal year end for Orchard Therapeutics?
Orchard Therapeutics's fiscal year ends in December. Where is Orchard Therapeutics based?
Orchard Therapeutics's address is: 108 Cannon Street, London, United Kingdom, EC4N 6EU What is Orchard Therapeutics's ISIN number?
Orchard Therapeutics's international securities identification number is: US68570P1012 What is Orchard Therapeutics's CUSIP number?
Orchard Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68570P101